Development-stage program failure
The company is still preclinical, so scientific or translational setbacks could eliminate asset value.
- Scope
- IBIO-600, IBIO-610 and other pipeline assets
- Materiality
- high
iBio, Inc.
iBio, Inc. is a U.S.-based preclinical biotechnology company focused on discovering and developing precision antibodies for cardiometabolic and obesity-related diseases. The company uses an AI and machine learning drug discovery platform, and it also develops and licenses early-stage biologic candidates and related intellectual property.
−34 583,0 %
−33 044,0 %
−75,0 %
7.85
| % | |
|---|---|
| AI Drug Discovery Platform | 10% Computational platform used to identify and optimize novel biologics and precision antibodies. |
| Preclinical Antibody Programs | 55% Early-stage therapeutic candidates such as IBIO-600 and IBIO-610 aimed at cardiometabolic and obesity targets. |
| Licensing and Collaboration Revenue | 20% Revenue from research services, licenses, and partner collaborations tied to discovery assets. |
| Intellectual Property and Platform Assets | 15% Owned patents, know-how, and related assets that support development and partnering. |
iBio’s direct customers are typically pharmaceutical and biotechnology partners that license programs, fund...
- Pharmaceutical licensing partnersprimary
Large or mid-sized drug companies that may license iBio candidates or IP to advance development and commercialization.
- Biotechnology collaboratorsprimary
Smaller biotech firms or research groups that collaborate on discovery, validation, or target-specific programs.
- Research services customerssecondary
Counterparties that pay for collaborative research, assay work, or related services tied to platform capabilities.
- Future therapeutic end usersemerging
Patients and clinicians in cardiometabolic and obesity indications who would use approved products if programs succeed.
iBio is headquartered in the United States and conducts its research and development primarily in San Diego...
- •United States is the operational base and primary R&D location
- •San Diego facilities house core research and lab activity
- •Worldwide licensing rights support global partnering potential
- •Third-party suppliers include U.S. and non-U.S. vendors
- •No meaningful country revenue disclosure was provided
iBio’s strategy is to advance a small number of preclinical antibody programs while using its AI platform to generate...
01
Advance preclinical pipeline assetsshort-term
Pipeline programs are the main source of future value and partnering leverage.
02
Expand AI-driven discovery outputmedium-term
The platform is intended to generate novel biologics that can be licensed or developed.
03
Secure collaborations and licensesmedium-term
Partnerships can fund development and create non-dilutive value from early assets.
iBio faces the typical risks of an early-stage biotech company: clinical and preclinical failure, regulatory...
Capital access and dilution
Long-duration R&D requires external funding before product revenue is available.
- Scope
- Equity issuance, warrants, and other financing sources
- Materiality
- high
Partner and collaborator dependence
Some programs rely on licensees or collaborators to advance development and commercialization.
- Scope
- Collaborative research and licensing arrangements
- Materiality
- medium
Competitive and regulatory pressure
Larger biotech and pharma firms have more resources for R&D, trials, and approvals.
- Scope
- AI drug discovery and precision antibody markets
- Materiality
- high
Supplier and outsourcing concentration
Key materials and services are outsourced and may have long lead times or limited alternatives.
- Scope
- Lonza Sales AG, Twist Bioscience and other third parties
- Materiality
- medium
Indefinite-lived intangible asset impairment
Could create non-cash impairment charges and affect equity value
Collaboration and license revenue recognition
Can cause uneven quarterly revenue
Fair value estimates and WACC
Affects asset carrying values and impairment conclusions
R&D expense classification
Influences operating loss and comparability across periods
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
IN8BIO, INC.
INAB · Biological Products, (No Diagnostic Substances)
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
OmniAb, Inc.
OABIW · Services-Commercial Physical & Biological Research
VERU INC.
VERU · Pharmaceutical Preparations
: 29/04/2026